Clinical Trials
23 trialsNCT03193281 2023-11-29
KISS
University of Auckland, New Zealand
Phase 2 Unknown
NCT04709731 2021-02-03
CarPAs
Associazione Italiana Pazienti Leucemia Mieloide Cronica
Phase 2 Unknown
NCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT02268370 2019-11-29
TRAD
University Health Network, Toronto
Phase 2 Unknown
NCT04043676 2019-08-02
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Fundación Teófilo Hernando, Spain
Phase 2 Unknown
NCT02889003 2018-03-22
PIO2STOP
Versailles Hospital
Phase 2 Unknown
NCT03241199 2017-08-08
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia
The University of Hong Kong
Phase 2 Unknown
NCT03205267 2017-07-02
BODO
University of Bonn
Phase 2 Unknown
NCT01690065 2016-05-11
NICE-BORA
Ulsan University Hospital
Phase 2 Unknown
NCT02422719 2016-05-11
REVITAL
Ulsan University Hospital
Phase 2 Unknown
NCT02687425 2016-02-22
SESPI
Tongji Hospital
Phase 2 Unknown
NCT01802450 2015-09-17
DASAPOST
PETHEMA Foundation
Phase 2 Unknown
NCT02511340 2015-07-30
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 2 Unknown
NCT00008307 2014-01-06
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01503502 2013-04-10
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT01221376 2013-03-26
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
Hospital Santa Marcelina
Phase 2 Unknown
NCT01627132 2012-06-25
Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial
Shimousa Hematology Study Group
Phase 2 Unknown
NCT01513603 2012-01-20
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
New York Medical College
Phase 2 Unknown
NCT01227135 2011-11-30
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
University of Glasgow
Phase 2 Unknown
NCT00112775 2011-06-07
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00598624 2009-08-11
AlloTreo
IRCCS San Raffaele
Phase 2 Unknown
NCT00146913 2007-04-27
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Hospices Civils de Lyon
Phase 2 Unknown
NCT00328237 2006-06-26
Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
Colorado Blood Cancer Institute
Phase 2 Unknown